Top
Begin typing your search above and press return to search.
keyboard_arrow_down
Login
exit_to_app
Farmer rage and Opposition parties
access_time 19 Sep 2020 6:51 AM GMT
access_time 19 Sep 2020 3:50 AM GMT
Going beyond birthday celebration
access_time 18 Sep 2020 6:05 AM GMT
Periyar@142-Revolutionary and Visionary
access_time 17 Sep 2020 11:57 AM GMT
The word of caution from the highest court
access_time 17 Sep 2020 6:31 AM GMT
DEEP READAll arrow_drop_down
The ogres in the mind
access_time 8 Sep 2020 11:27 AM GMT
Why worry about populism?
access_time 4 Sep 2020 9:51 AM GMT
Media mind-set towards minorities
access_time 15 July 2020 4:29 PM GMT
exit_to_app
Homechevron_rightBusinesschevron_rightLupin launches chronic ...

Lupin launches chronic angina treatment drug in the US

text_fields
bookmark_border
Lupin launches chronic angina treatment drug in the US
cancel

New Delhi: Drug maker Lupin Thursday announced exclusive launch of Ranolazine extended-release (ER) tablets, indicated for the treatment of chronic angina, in the US market.

The newly launched product, in strengths of 500 mg and 1,000 mg, is a generic version of Gilead Sciences' Ranexa ER tablets, Lupin said in BSE filing.

Quoting IQVIA MAT December 2018 data, Lupin said Ranolazine ER tablets, 500 mg and 1,000 mg had an annual sales of approximately USD 945 million in the US.

"This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics," Lupin Managing Director Nilesh Gupta said.

"Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to the market, he added.

Shares of Lupin were trading 0.29 per cent up at Rs 769.95 apiece on BSE.

Show Full Article
TAGS:
Next Story